Contact
Please use this form to send email to PR contact of this press release:
CoreRx, Inc. announces that its client Bionpharma Inc. has received FDA approval for generic oral suspension Banzel®
TO:
Mark DaFonseca, Chief Business Officer
CoreRx, Inc.
+1 727-259-6950